Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 480-489

  Bendell, Johanna C ^a   Gordon, Michael S ^b   Hurwitz, Herbert I ^c   Jones, Suzanne F ^a   Mendelson, David S ^b   Blobe, Gerard C ^c   Agarwal, Neeraj ^d   Condon, Carolyn H ^e   Wilson, Dawn ^e   Pearsall, Amelia E ^e   Yang, Yijun ^e   McClure, Ty ^e   Attie, Kenneth M ^e   Sherman, Matthew L ^e   Sharma, Sunil ^d  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Pinnacle Oncology Hematology   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Acceleron Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALANTERCEPT; FUROSEMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CARCINOID; CLINICAL ARTICLE; COHORT ANALYSIS; COLLOID CARCINOMA; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; CORRELATIONAL STUDY; DIGESTIVE SYSTEM PERFORATION; DIURETIC THERAPY; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GRANULOSA CELL TUMOR; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART MURMUR; HEMOLYSIS; HUMAN; HYPERTENSION; HYPERVOLEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; METABOLISM; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SMALL INTESTINE CARCINOMA; TELANGIECTASIA; THROMBOCYTOPENIA; TUMOR BLOOD FLOW; TUMOR METABOLIC ACTIVITY;

ACTIVIN RECEPTORS, TYPE II; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LIGANDS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECOMBINANT FUSION PROTEINS; TELANGIECTASIS; TREATMENT OUTCOME;

EID: 84892774957     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1840     Document Type: Article

References (47)

1. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
2. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529-39.
3. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8: 618-31.
4. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011;81(Suppl 1):24-9.
5. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
6. Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr Opin Oncol 2010;22:586-91.
7. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010;13:1-14.
8. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
9. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8: 210-21.
10. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-14.
11. Townson SA, Martinez-Hackert E, Greppi C, Lowden P, Sako D, Liu J, et al. Specificity and structure of a high affinity activin receptorlike kinase 1 (ALK1) signaling complex. J Biol Chem 2012;287: 27313-25.
12. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-b1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000;97:2626-31.
13. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000;26:328-31.
14. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13: 189-95.
15. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43:97-110.
16. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003;12:473-82.
17. Seki T, Yun J,OhSP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003;93:682-9.
18. Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, et al. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti- VEGF therapies. Cancer Res 2011;71:1362-73.
19. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007;109: 1953-61.
20. Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmers TA, et al. BMP9and BMP10 are critical for postnatal retinal vascular remodeling. Blood 2012;119:6162-71.
21. Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002;100: 4495-501.
22. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007;120:964-72.
23. David L, Feige JJ, Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 2009;20:203-12.
24. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, et al. Genetic and pharmacological targeting of activin receptorlike kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010;207:85-100.
25. Niessen K, Zhang G, Ridgway JB, Chen H, Yan M. ALK1 signaling regulates early postnatal lymphatic vessel development. Blood 2010;115:1654-61.
26. Duong T, Koopman P, Francois M. Tumor lymphangiogenesis as apotential therapeutic target. J Oncol 2012;2012:204946.
27. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9:379-88.
28. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification ofFDGwhole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320-33.
29. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
30. Paulson RF, Shi L, Wu DC. Stress erythropoiesis: new signals and new stress progenitor cells. Curr Opin Hematol 2011;18:139-45.
31. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 2012;18:4820-9.
32. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132-43.
33. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009;43:490-501.
34. Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: A review. Oncologist 2011;16:432-44.
35. des Guetz G, Uzzan B, Chouahnia K, Morere JF. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol 2011;6:197-202.
36. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007;13: 770s-6s.
37. Contractor KB, Aboagye EO.Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009;50(Suppl 1): 97S-105S.
38. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87.
39. O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012;9:167-77.
40. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26:4572-8.
41. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011;117:6999-7006.
42. van Meeteren LA, Goumans MJ, ten Dijke P. TGF-b receptor signaling pathways in angiogenesis; emerging targets for antiangiogenesis therapy. Curr Pharm Biotechnol 2011;12:2108-20.
43. Pearsall S, Solban N, Attie KM, Sherman ML, Kumar R. BMP9 as a potential biomarker for dalantercept efficacy against ALK1-mediated angiogenesis in head and neck cancer. J Clin Oncol 30, 2012:(October 20 suppl; abstr 30).
44. van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 2012;287:18551-61.
45. Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 2011;286: 30034-46.
46. Nolan-Stevaux O, Zhong W, Culp S, Shaffer K, Hoover J, Wickramasinghe D, et al. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS One 2012;7:e50920.
47. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11:79-89.